Should we shock PEA/asystole? : A multicenter prospective study on Echo Visualization of Occult Ventricular Fibrillation in Out-of-Hospital Cardiac Arrest 

Should we shock PEA/asystole? : A multicenter prospective study on Echo Visualization of Occult Ventricular Fibrillation in Out-of-Hospital Cardiac Arrest 

by | Aug 10, 2026 | cardiac arrest, Critical Care, Featured, Journal Club, Ultrasound

Gaspari et al. Ann Emerg Med. 2025 Oct;86(4):328-336. doi: 10.1016/j.annemergmed.2025.04.014. Question:  To identify the prevalence of non-shockable ECG rhythm but ventricular fibrillation (VF) by Echo in out-of-hospital cardiac arrest (OHCA). To determine the...
Personalized Hemodynamic Resuscitation Targeting Capillary Refill Time in Early Septic Shock: The ANDROMEDA-SHOCK-2 Randomized Clinical Trial

Personalized Hemodynamic Resuscitation Targeting Capillary Refill Time in Early Septic Shock: The ANDROMEDA-SHOCK-2 Randomized Clinical Trial

by , | Jun 1, 2026 | Critical Care, Journal Club, Resuscitation

Personalized Hemodynamic Resuscitation Targeting Capillary Refill Time in Early Septic Shock: The ANDROMEDA-SHOCK-2 Randomized Clinical Trial.  Hernandez G, ANDROMEDA-SHOCK-2 Investigators for the ANDROMEDA Research Network JAMA. 2025 Oct 29:e2520402. doi:...
Tenecteplase versus standard medical treatment for basilar artery occlusion within 24 h (TRACE-5): a multicentre, prospective, randomised, open-label, blinded-endpoint, superiority, phase 3 trial.

Tenecteplase versus standard medical treatment for basilar artery occlusion within 24 h (TRACE-5): a multicentre, prospective, randomised, open-label, blinded-endpoint, superiority, phase 3 trial.

by , | May 25, 2026 | Journal Club, Neurology

Tenecteplase versus standard medical treatment for basilar artery occlusion within 24 h (TRACE-5): a multicentre, prospective, randomised, open-label, blinded-endpoint, superiority, phase 3 trial Xiong Y, Et al. Lancet. 2026 Feb 21;407(10530):763-772. doi:...
Comparison of inhalational methoxyflurane, intranasal fentanyl, and intravenous morphine for treatment of prehospital acute pain in Norway (PreMeFen): a randomised, non-inferiority, three-arm, phase 3 trial.

Comparison of inhalational methoxyflurane, intranasal fentanyl, and intravenous morphine for treatment of prehospital acute pain in Norway (PreMeFen): a randomised, non-inferiority, three-arm, phase 3 trial.

by , | May 18, 2026 | Anesthesiology, Featured, Journal Club, Pain Medicine

Comparison of inhalational methoxyflurane, intranasal fentanyl, and intravenous morphine for treatment of prehospital acute pain in Norway (PreMeFen): a randomised, non-inferiority, three-arm, phase 3 trial Simensen R, et al. Lancet. 2025 Dec 20;406(10522):2957-2967....